Neuren has signed away all rights to trofinetide in North America.
An exclusive license agreement was signed with Acadia for the North American development and commercialization of trofinetide for all indications, not just Rett syndrome and Fragile X.
- Forums
- ASX - By Stock
- Ann: New patent issued to 2032 for Neuren's trofinetide in Canada
Neuren has signed away all rights to trofinetide in North...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B |
Open | High | Low | Value | Volume |
$20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 249 | $20.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.31 | 790 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 249 | 20.150 |
2 | 815 | 20.110 |
1 | 99 | 20.100 |
1 | 912 | 20.090 |
1 | 790 | 20.070 |
Price($) | Vol. | No. |
---|---|---|
20.310 | 790 | 1 |
20.350 | 790 | 1 |
20.390 | 1640 | 2 |
20.420 | 790 | 1 |
20.580 | 2400 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |